Why the study?
Does ECMO provide effective life support for neonates with severe, refractory enteroviral myocarditis?
Does ECMO provide effective life support for neonates with severe, refractory enteroviral myocarditis?
ECMO should be considered early in neonates with enteroviral myocarditis who experience rapid clinical and echocardiographic deterioration despite adequate inotropic support.
Answers are grounded in this paper and cite their sources.
Mixed ECMO outcomes in neonatal enteroviral myocarditis; leaves open its role and requires prospective study before practice change.
Enteroviruses are a leading cause of viral infections in children. While most enteroviral infections are mild and self-limiting, severe disease such as a viral sepsis syndrome, myocarditis, hepatitis and meningoencephalitis may occur. We present two cases of neonatal enteroviral myocarditis. Cardiorespiratory failure occurred in both cases, and severe shock refractory to conventional treatment required support with extracorporeal membrane oxygenation (ECMO). One child with coxsackievirus B3 myocarditis failed to recover and died after 3 weeks on ECMO, while one child could be decannulated successfully after 9 days of ECMO and recovered completely subsequently. In conclusion, neonatal myocarditis has a very high mortality, and ECMO should be considered early in neonates with rapid clinical and echocardiographic deterioration despite adequate inotropic support.
No takes yet. Share an insight, caveat, or question.
Schlapbach et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: